• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Evolving concepts in the management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation
Eur J Intern Med. 2022 May 24:S0953-6205(22)00171-6. doi: 10.1016/j.ejim.2022.05.002. Online ahead of print.ABSTRACTThromboembolic and bleeding complications negatively impact recovery and survival after transcatheter aortic valve implantation (TAVI). Particularly, there is a considerable risk of ischaemic stroke and vascular access related bleeding, as well as spontaneous gastro-intestinal bleeding. Therefore, benefit and harm of antithrombotic therapy should be carefully balanced. This review summarizes current evidence on peri- and post-procedural antithrombotic treatment. Indeed, in recent years, the management of anti...
Source: European Journal of Internal Medicine - May 27, 2022 Category: Internal Medicine Authors: Dirk Jan van Ginkel Willem L Bor Leo Veenstra Arnoud W J van 't Hof Enrico Fabris Source Type: research

Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations
Eur J Intern Med. 2022 May 4:S0953-6205(22)00166-2. doi: 10.1016/j.ejim.2022.04.023. Online ahead of print.ABSTRACTClinical practice in atrial fibrillation (AF) patient management is constantly evolving. In the past 3 years, various new AF guidelines or focused updates have been published, given this rapidly evolving field. In 2019, the American College of Cardiology/American Heart Association published a focused update of the 2014 guidelines. In 2020, both the European Society of Cardiology and the Canadian Cardiovascular Society released their new guidelines. Finally, the most recent guidelines were those published in 20...
Source: European Journal of Internal Medicine - May 7, 2022 Category: Internal Medicine Authors: Jacopo Francesco Imberti Davide Antonio Mei Marco Vitolo Niccol ò Bonini Marco Proietti Tatjana Potpara Gregory Y H Lip Giuseppe Boriani Source Type: research

P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis
CONCLUSIONS: Early administration of P2Y12 inhibitors plus aspirin in patients with acute non-cardioembolic minor ischemic stroke or TIA reduced the incidence of ischemic stroke recurrence, impacting more significantly than the increased bleeding risk and influencing patients' quality of life by reducing disabling stroke.PMID:35331593 | DOI:10.1016/j.ejim.2022.03.017
Source: European Journal of Internal Medicine - March 25, 2022 Category: Internal Medicine Authors: Fulvio Pomero Eleonora Galli Marta Bellesini Lorenzo Maroni Alessandro Squizzato Source Type: research

Extended venous thromboprophylaxis in patients hospitalized for acute ischemic stroke: A systematic review and meta-analysis
CONCLUSION: In patients hospitalized for acute ischemic stroke, the net clinical benefit may favor extended venous thromboprophylaxis for four to five weeks over standard thromboprophylaxis.PMID:34649783 | DOI:10.1016/j.ejim.2021.09.016
Source: European Journal of Internal Medicine - October 15, 2021 Category: Internal Medicine Authors: Emanuele Valeriani Nicola Potere Matteo Candeloro Silvia Spoto Ettore Porreca Anne Ws Rutjes Marcello Di Nisio Source Type: research

Oral anticoagulants vs antiplatelets in cryptogenic stroke with potential cardiac emboli: Meta-analysis
CONCLUSIONS: OACs compared with antiplatelet therapies were associated with a reduced recurrent ischemic stroke risk and OACs might be a viable non-procedural alternative in patients with cryptogenic stroke and potential cardiac emboli.PMID:34419310 | DOI:10.1016/j.ejim.2021.08.002
Source: European Journal of Internal Medicine - August 22, 2021 Category: Internal Medicine Authors: Wen-Yi Huang Bruce Ovbiagele Meng Lee Source Type: research

Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study
CONCLUSIONS: More than two thirds of the interventions were performed with uninterrupted dabigatran therapy, of which most were AF-cardioversions. Uninterrupted dabigatran therapy was associated with low major bleeding and stroke/systemic embolism risk, supporting the favourable safety and effectiveness profile of dabigatran in clinical practice-based settings.PMID:34120814 | DOI:10.1016/j.ejim.2021.05.020
Source: European Journal of Internal Medicine - June 14, 2021 Category: Internal Medicine Authors: Sake J van der Wall Gregory Y H Lip Christine Teutsch Oskars Kalejs Philippe Lyrer Christian Hall Sergio J Dubner Hans-Christoph Diener Jonathan L Halperin Chang Sheng Ma Kenneth J Rothman Kristina Zint Dongmei Zhai Menno V Huisman GLORIA-AF Investigators Source Type: research

Trends and outcomes of device-related 30-day readmissions after left ventricular assist device implantation.
CONCLUSION: Over one-fourth of LVAD recipients have 30-day readmissions, with most of them occurring within 15 days. Most frequent cause of readmission was gastrointestinal bleeding, which was associated with the lowest in-hospital mortality among other complications. PMID: 33039191 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - October 7, 2020 Category: Internal Medicine Authors: Briasoulis A, Ueyama H, Kuno T, Asleh R, Alvarez P, Malik AH Tags: Eur J Intern Med Source Type: research

Safety and efficacy of anticoagulant monotherapy in atrial fibrillation and stable coronary artery disease: A systematic review and meta-analysis.
CONCLUSION: OAC monotherapy might have a lower incidence of major bleeding events with no higher overall risk of MACE, ischemic stroke and all-cause mortality compared to the combined therapy group. PMID: 32709546 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - July 21, 2020 Category: Internal Medicine Authors: Ullah W, Sattar Y, Shaukat M, Fischman DL Tags: Eur J Intern Med Source Type: research

Antithrombotic treatment in patients with atrial fibrillation undergoing coronary angioplasty: rational convincement and supporting evidence.
CONCLUSIONS: Our findings suggest that DT is safer than TT with regard to occurrence of major bleeding. DT with a direct oral anticoagulant plus clopidogrel at discharge could be effective in most patients, maintaining aspirin in periprocedural phase and as longer "tailored" treatment for patients at higher ischemic risk. PMID: 32063489 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - February 12, 2020 Category: Internal Medicine Authors: Ricottini E, Nenna A, Melfi R, Giannone S, Lusini M, Sciascio GD, Chello M, Ussia GP, Grigioni F Tags: Eur J Intern Med Source Type: research

One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study.
CONCLUSIONS: The follow-up of the BLITZ-AF study provide an up to date picture of the clinical course of patients with AF, who appear frequently affected by heart failure and severe comorbidities which might have led to the high mortality rate. PMID: 31952984 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - January 13, 2020 Category: Internal Medicine Authors: Cemin R, Colivicchi F, Maggioni AP, Boriani G, De Luca L, Di Lenarda A, Di Pasquale G, Fabbri G, Lucci D, Gulizia MM, On the behalf of BLITZ-AF Investigators Tags: Eur J Intern Med Source Type: research

Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries?
Abstract Proton pump inhibitors (PPIs) are among the most widely prescribed agents, either for treatment or prophylaxis of gastrointestinal (GI) disease, that are often administered for prolonged or chronic use. Patients with cardiovascular (CV) disease frequently receive PPIs for prophylaxis against GI bleeding due to common use of antithrombotic drugs. Over the last several years there is a growing number of reports associating chronic PPI use with a variety of serious CV and non-CV adverse effects. In this context, PPI use has been independently associated with an increased risk of CV morbidity (myocardial infa...
Source: European Journal of Internal Medicine - November 29, 2019 Category: Internal Medicine Authors: Manolis AA, Manolis TA, Melita H, Katsiki N, Manolis AS Tags: Eur J Intern Med Source Type: research

Use of proton pump inhibitors is associated with an increase in adverse cardiovascular events in patients with hemodialysis: Insight from the kids registry.
CONCLUSIONS: These results indicate that the use of PPIs in patients with maintenance hemodialysis might increase mortality and cardiovascular events without decreasing the risk of bleeding. Therefore, it should always be analyzed if a patient truly needs PPIs. PMID: 31735546 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - November 13, 2019 Category: Internal Medicine Authors: Kosedo I, Tokushige A, Takumi T, Yoshikawa A, Teraguchi K, Takenouchi K, Shiraishi K, Ikeda D, Imamura M, Sonoda T, Kanda D, Ikeda Y, Ido A, Ohishi M Tags: Eur J Intern Med Source Type: research

Pages: 1  2  3